Guardant Health Inc. Common Stock vs Zoetis Inc — how do they compare? Guardant Health Inc. Common Stock trades at $165.58 (market cap $22.58B), while Zoetis Inc trades at $73.02 (market cap $29.57B). The key difference: Zoetis Inc is the larger of the two by market cap, and Zoetis Inc pays a 2.96% dividend while Guardant Health Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Guardant Health Inc. Common Stock for 0 Days and Zoetis Inc for 70 Days on average.
| GH | ZTS | |
|---|---|---|
Market Cap | $22.58B | $29.57B |
Volume | 2,200,599 | 4,128,093 |
Sector | Health | Health |
52-Week High | $187.22 | $147.53 |
52-Week Low | $61.73 | $69.09 |
Typical Hold Time | 0 Days | 70 Days |
Enterprise Value | $23.22B | $37.13B |
Dividend Yield | — | 2.96% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Zoetis (ZTS) trades at $73.08, up 2.47% on the day, but remains in a bearish technical trend with support near $70. Fundamentally, the company reported strong 2025 results with $9.47B revenue, $2.67B net income, and robust margins, though recent quarters show mixed earnings performance. Analyst consensus is a Buy with a $87.33 price target, but sentiment is cautious due to U.S. pet care weakness and competitive pressures.
The stock offers value with a P/E of 11.67 and a 3% dividend yield, but near-term headwinds include declining U.S. companion animal sales and margin compression. Long-term growth prospects remain intact given industry leadership and international resilience, making it a contrarian opportunity for patient investors despite technical and competitive risks.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Guardant Health develops blood tests for cancer care. Its tests support genomic profiling, cancer screening, recurrence monitoring, and treatment decisions.
Read more on GH →Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →